Search Result

Pathways Recommended:	Neuronal Signaling

Results for "

neuronal injury

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Akt (3) Amino Acid Derivatives (1) AMPK (1) Amyloid-β (2) Apoptosis (9) ASK1 (2) Atg8/LC3 (1) ATP Synthase (1) Biochemical Assay Reagents (1) Cathepsin (1) Cholinesterase (ChE) (1) Endogenous Metabolite (1) ERK (1) Gap Junction Protein (2) Glutathione Peroxidase (1) Glycosidase (1) iGluR (1) JNK (1) Keap1-Nrf2 (3) LRRK2 (2) mGluR (2) Mitochondrial Metabolism (1) mTOR (1) Necroptosis (1) NO Synthase (3) NOD-like Receptor (NLR) (1) PARP (1) Potassium Channel (1) Proteasome (2) RAR/RXR (1) Reactive Oxygen Species (2) Sodium Channel (1) STAT (2) TGF-beta/Smad (1) Toll-like Receptor (TLR) (1) Trk Receptor (2) TRP Channel (4)
By Research Areas:	Cancer (4) Cardiovascular Disease (4) Endocrinology (1) Inflammation/Immunology (7) Metabolic Disease (5) Neurological Disease (37)

By Targets:

Adrenergic Receptor (1)

Akt (3)

Amino Acid Derivatives (1)

AMPK (1)

Amyloid-β (2)

Apoptosis (9)

ASK1 (2)

Atg8/LC3 (1)

ATP Synthase (1)

Biochemical Assay Reagents (1)

Cathepsin (1)

Cholinesterase (ChE) (1)

Endogenous Metabolite (1)

ERK (1)

Gap Junction Protein (2)

Glutathione Peroxidase (1)

Glycosidase (1)

iGluR (1)

JNK (1)

Keap1-Nrf2 (3)

LRRK2 (2)

mGluR (2)

Mitochondrial Metabolism (1)

mTOR (1)

Necroptosis (1)

NO Synthase (3)

NOD-like Receptor (NLR) (1)

PARP (1)

Potassium Channel (1)

Proteasome (2)

RAR/RXR (1)

Reactive Oxygen Species (2)

Sodium Channel (1)

STAT (2)

TGF-beta/Smad (1)

Toll-like Receptor (TLR) (1)

Trk Receptor (2)

TRP Channel (4)

By Research Areas:

Cancer (4)

Cardiovascular Disease (4)

Endocrinology (1)

Inflammation/Immunology (7)

Metabolic Disease (5)

Neurological Disease (37)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-118355

ALLM Calpain inhibitor II	Proteasome Cathepsin	Neurological Disease
ALLM (Calpain inhibitor II) is a potent inhibitor of calpain and cathepsin proteases. ALLM inhibits neuronal cell death and improves chronic neurological function after spinal cord injury (SCI) .

HY-B0792

CZC-54252	LRRK2	Neurological Disease
CZC-54252 is a potent and selective LRRK2 inhibitor with IC₅₀s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. CZC-54252 attenuates G2019S LRRK2-induced human neuronal injury with an EC₅₀ of ~1 nM. CZC-54252 has a neuroprotective activity .

HY-B0792A

CZC-54252 hydrochloride	LRRK2	Neurological Disease
CZC-54252 hydrochloride is a potent and selective LRRK2 inhibitor with IC₅₀s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. G2019S LRRK2-induced human neuronal injury is attenuated by CZC-54252 hydrochloride with an EC₅₀ of ~1 nM.CZC-54252 hydrochloride has a neuroprotective activity .

HY-100206

5α-Androstane-3β,5,6β-triol	AMPK	Neurological Disease
5α-Androstane-3β,5,6β-triol is a neuroprotectant. 5α-Androstane-3β,5,6β-triol can remarkably reverse intracellular acidification and alleviate neuronal injury through the inhibition of AMPK signaling. 5α-Androstane-3β,5,6β-triol remarkably reduced the infarct volume and attenuated neurologic impairment in acute ischemic stroke models of middle cerebral artery occlusion in vivo .

HY-B0985A

Phenazopyridine 2 Publications Verification	TRP Channel	Neurological Disease
Phenazopyridine is a competitive SARM1 inhibitor, with IC₅₀ 145 μM. Phenazopyridine is a TRPM8 antagonist. Phenazopyridine has a local anesthetic/analgesic effect. Phenazopyridine is used to relieve painful symptoms of conditions such as cystitis and urethritis. Phenazopyridine can promote neuronal differentiation and can also be used in the study of traumatic brain injury, peripheral neuropathy and neurodegenerative diseases .

HY-B0985

Phenazopyridine hydrochloride 2 Publications Verification	TRP Channel	Neurological Disease
Phenazopyridine hydrochlorideis a competitive SARM1 inhibitor, with IC₅₀ 145 μM. Phenazopyridine hydrochlorideis a TRPM8 antagonist. Phenazopyridine hydrochloride has a local anesthetic/analgesic effect. Phenazopyridine hydrochlorideis used to relieve painful symptoms of conditions such as cystitis and urethritis. Phenazopyridine hydrochloridecan promote neuronal differentiation and can also be used in the study of traumatic brain injury, peripheral neuropathy and neurodegenerative diseases .

HY-59291

Levacetylleucine N-Acetyl-L-leucine	Amino Acid Derivatives	Neurological Disease Metabolic Disease Inflammation/Immunology
Levacetylleucine (N-acetyl-L-leucine), an orally bioavailable and brain-penetrant compound, is an acetylated derivative of amino acid Leucine. Levacetylleucine is the active form of N-acetyl-leucine (NAL). Levacetylleucine attenuates neuronal death and neuroinflammation in the cortical tissue of mice. Levacetylleucine also potentially improves ameliorates lysosomal and metabolic dysfunction. Levacetylleucine improves compensation of postural symptoms after unilateral chemical labyrinthectomy (UL) in rats. Levacetylleucine is promising for research of neurological manifestations of Niemann-Pick disease type C, traumatic brain injury and neurodegeneration prevention .

HY-P2275

Peptide5	Gap Junction Protein	Neurological Disease
Peptide5, a connexin 43 mimetic peptide, reduce animals swelling, astrogliosis, and neuronal cell death after spinal cord injury

HY-B0985R

Phenazopyridine (hydrochloride) (Standard)	TRP Channel	Neurological Disease
Phenazopyridine (hydrochloride) (Standard) is the analytical standard of Phenazopyridine (hydrochloride). This product is intended for research and analytical applications. Phenazopyridine hydrochlorideis a competitive SARM1 inhibitor, with IC₅₀ 145 μM. Phenazopyridine hydrochlorideis a TRPM8 antagonist. Phenazopyridine hydrochloride has a local anesthetic/analgesic effect. Phenazopyridine hydrochlorideis used to relieve painful symptoms of conditions such as cystitis and urethritis. Phenazopyridine hydrochloridecan promote neuronal differentiation and can also be used in the study of traumatic brain injury, peripheral neuropathy and neurodegenerative diseases .

HY-103563

3-MATIDA	mGluR	Neurological Disease
3-MATIDA is a metabolic glutamate 1 (mGlu1) receptor antagonist. 3-MATIDA alleviates neuronal death in cerebral ischemia models. 3-MATIDA can be used in the study of neuronal injury and epileptiform activity after ischemia .

HY-P1061

Colivelin Maximum Cited Publications 58 Publications Verification	STAT Amyloid-β	Neurological Disease
Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3?in vitro . Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin has the potential for the treatment of alzheimer's disease and ischemic brain injury

HY-N4098

Incensole Acetate	Apoptosis	Neurological Disease
Incensole acetate is a main constituent of Boswellia carterii resin, has neuroprotective effects against neuronal damage in traumatic and ischemic head injury. Incensole acetate reduces Aβ25–35-triggered apoptosis in hOBNSCs .

HY-P1061A

Colivelin TFA Maximum Cited Publications 58 Publications Verification	STAT Amyloid-β Apoptosis	Neurological Disease
Colivelin TFA is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro . Colivelin TFA exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin TFA has the potential for the treatment of alzheimer's disease and ischemic brain injury .

HY-114520

TT01001	Mitochondrial Metabolism Apoptosis Reactive Oxygen Species	Neurological Disease Metabolic Disease
TT01001 is a potent and orally active mitoNEET ligand. TT01001 reduces oxidative stress injury and neuronal apoptosis by improving mitochondrial dysfunction. TT01001 improves type II diabetes without causing weight gain .

HY-P2275B

Peptide5 TFA	Gap Junction Protein NOD-like Receptor (NLR)	Inflammation/Immunology
Peptide5 TFA, a connexin 43 mimetic peptide, reduces animals swelling, astrogliosis, and neuronal cell death after spinal cord injury. Peptide5 TFA also inhibits NLRP3 inflammasome, and is an anti-inflammatory agent .

HY-114869

DPQ 1 Publications Verification	PARP	Neurological Disease
DPQ is a blood-brain barrier permeable and selective PARP-1 inhibitor that blocks PARP-1-mediated DNA damage repair and NAD ⁺/ATP consumption, thereby inhibiting excessive inflammatory responses. DPQ inhibits NF-κB pathway activation, reduces the expression of pro-inflammatory factors (such as TNF-α, IL-6) and oxidative stress. DPQ can be used in inflammation-related studies of acute lung injury, myocardial infarction, and neurodegenerative diseases .

HY-148629

GDC-0134	JNK	Neurological Disease
GDC-0134 is a potent, selective, orally active, brain-penetrant dual leucine zipper kinase (DLK) inhibitor. GDC-0134 blocks DLK activity in cellular assays and in animal models of neuronal injury. GDC-0134 can be used for the study of amyotrophic lateral sclerosis (ALS) .

HY-N4098R

Incensole Acetate (Standard)	Apoptosis	Neurological Disease
Incensole Acetate (Standard) is the analytical standard of Incensole Acetate. This product is intended for research and analytical applications. Incensole acetate is a main constituent of Boswellia carterii resin, has neuroprotective effects against neuronal damage in traumatic and ischemic head injury. Incensole acetate reduces Aβ25–35-triggered apoptosis in hOBNSCs .

HY-N1163

Tetrahydroalstonine (-)-Tetrahydroalstonine	Adrenergic Receptor Atg8/LC3 Akt mTOR	Neurological Disease Endocrinology
Tetrahydroalstonine ((-)-Tetrahydroalstonine) is an indole alkaloid and a selective α₂-adrenergic receptor antagonist. Tetrahydroalstonine exhibits certain neuroprotective effects. Tetrahydroalstonine can regulate autophagy-lysosomal function by activating the Akt/mTOR pathway, significantly reducing OGD/R-induced primary cortical neuronal injury .

HY-101446

HIOC	Trk Receptor ERK Apoptosis	Neurological Disease
HIOC is a potent and selective activator of TrkB (tropomyosin related kinase B) receptor. HIOC can pass the blood-brain and blood-retinal barriers.HIOC activates TrkB/ERK pathway and decreases neuronal cell apoptosis. HIOC attenuates early brain injury after SAH (subarachnoid hemorrhage). HIOC shows protective activity in an animal model for light-induced retinal degeneration .

HY-170790

HZS60	TRP Channel	Neurological Disease
HZS60 is a NMDAR/TRPM4 inhibitor with brain permeability that can improve cerebral ischemia. HZS60 has significant neuroprotective effects on primary neuronal ischemic damage caused by NMDA and oxygen-glucose deprivation/reoxygenation. HZS60 exhibits good pharmacokinetic characteristics and can inhibit cerebral ischemia-reperfusion injury. HZS60 can be used as a potential inhibitor of ischemic stroke .

HY-126758

Ludartin	Apoptosis Glutathione Peroxidase	Inflammation/Immunology
Ludartin a sesquiterpene lactone, which can be isolated from the plant Artemisia carruthii Wood. Ludartin reduces the expression of myeloperoxidase and malondialdehyde, enhances the expression of glutathione and superoxide dismutase in spinal cord tissue. Ludartin inhibits neuronal apoptosis. Ludartin inhibits the upregulation of tumor necrosis factor-α, interleukin-1β, and interleukin-6. Ludartin improves the motor function of rats with spinal cord injury .

HY-116171

(Rac)-Calpain Inhibitor XII	Proteasome	Cardiovascular Disease Neurological Disease
(Rac)-Calpain Inhibitor XII is a reversible and selective inhibitor of calpain I (μ-calpain, K_i=19 nM). (Rac)-Calpain Inhibitor XII has lower affinities for calpain II (m-calpain, K_i=120 nM) and cathepsin B (K_i=750 nM). (Rac)-Calpain Inhibitor XII has the potential for studying the role of calpains in diverse processes, including neutrophil chemotaxis, neuronal signaling, and cardiac response to injury .

HY-P2325

Exoenzyme C3, clostridium botulinum	Biochemical Assay Reagents	Neurological Disease
Exoenzyme C3, clostridium botulinum is a promising agent to inactivate RhoA in neurons due to preventing the detrimental effect of active Rho in the recovery of injured neuronal systems. Exoenzyme C3, clostridium botulinum is used for the study of post-traumatic neuro-regeneration .

HY-12119

GW274150 2 Publications Verification	NO Synthase	Neurological Disease Inflammation/Immunology
GW274150 is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC₅₀=2.19 μM; K_d=40 nM) and rat iNOS (ED₅₀=1.15 μM). GW274150 also displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 exerts a protective role in an acute model of lung injury inflammation .

HY-P5754B

TAT-NEP1-40 acetate	Apoptosis	Neurological Disease
TAT-NEP1-40 acetate is a therapeutic candidate for axonal regeneration and functional recovery after stroke. TAT-NEP1-40 acetate can protect PC12 cells against oxygen and glucose deprivation (OGD) and promote neurite outgrowth. TAT-NEP1-40 acetate protects the brain against ischemia/reperfusion injury through inhibition of neuronal apoptosis. TAT-NEP1-40 acetate can be efficiently delivered into the rat brains .

HY-12119B

GW274150 dihydrochloride	NO Synthase	Neurological Disease Inflammation/Immunology
GW274150 (dihydrochloride) is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC₅₀=2.19 μM; K_d=40 nM) and rat iNOS (ED₅₀=1.15 μM). GW274150 (dihydrochloride) displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 (dihydrochloride) exerts a protective role in an acute model of lung injury inflammation .

HY-12119A

GW274150 phosphate 2 Publications Verification	NO Synthase	Neurological Disease Inflammation/Immunology
GW274150 phosphate is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC₅₀=2.19 μM; K_d=40 nM) and rat iNOS (ED₅₀=1.15 μM). GW274150 phosphate displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 phosphate exerts a protective role in an acute model of lung injury inflammation .

HY-172876

FLY26	iGluR Reactive Oxygen Species Trk Receptor	Cardiovascular Disease
FLY26 is a selective partial GluN2B antagonist with an IC₅₀ value of 0.64 μM. FLY26 partially inhibits the GluN2B subunit of NMDA receptors, reduces calcium ion influx and reactive oxygen species (ROS) production and activates the BDNF/TrkB/CREB neuroprotective signaling pathway to alleviate neuronal excitotoxicity and mitochondrial dysfunction. FLY26 is promising for research of neurological deficits caused by cerebral ischemia-reperfusion injury .

HY-162347

Nav1.7-IN-13	Sodium Channel	Neurological Disease
Nav1.7-IN-13 (compound 3g) is a sodium channel inhibitor that significantly inhibits Veratridine (HY-N6691)-induced neuronal activity. Nav1.7-IN-13 inhibits total Na+ current in DRG neurons in a concentration-dependent manner; slows down the activation of Navs. Nav1.7-IN-13 significantly alleviated mechanical pain behavior in a rat model of nerve injury (SNI) and had analgesic activity .

HY-111573

KCL-286 C286	RAR/RXR	Others Neurological Disease Inflammation/Immunology
KCL-286 (C286) is an orally active and brain-penetrant retinoic acid receptor (RAR) β2 agonist (EC₅₀ = 1.9 nM). KCL-286 targets RARβ2 with good selectivity over RAR α (EC₅₀ = 26 nM) and RAR γ (EC₅₀ = 11 nM). KCL-286 activates RARβ2 in the injured neurons. KCL-286 induces axonal regeneration of both spinal and sensory nerves through the inhibitory environment of the CNS, modulates neuroinflammation and extracellular matrix molecules. KCL-286 can modulate the expression of CSPGs by neuronal secretion of decorin which promotes myelination and aids axonal growth. KCL-286 can be studied in research for area such as spinal cord injury and traumatic nerve injury .

HY-N8161

Kaempferol-3,7-di-O-β-glucoside Kaempferol 3,7-diglucoside	Glycosidase Cholinesterase (ChE)	Neurological Disease
Kaempferol-3,7-di-O-β-glucoside (Kaempferol 3,7-diglucoside), a flavonol, possesses enzyme inhibition property towards α-amylase, α-glucosidase and Acetylcholinesterase. Kaempferol-3,7-di-O-β-glucoside protects differentiating neuronal cells, SH-SY5Y from Amyloid β peptide-induced injury. Kaempferol-3,7-di-O-β-glucoside has the potential for Alzheimer's research .

HY-P99359

Elezanumab ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)	TGF-beta/Smad	Metabolic Disease
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC₅₀ around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .

HY-100403

Ro 67-7476 10+ Cited Publications	mGluR	Cancer
Ro 67-7476 is a potent positive allosteric modulator of mGluR₁ and potentiates glutamate-induced calcium release in HEK293 cells expressing rat mGluR1a with an EC₅₀ of 60.1 nM . Ro 67-7476 is a potent P-ERK1/2 agonist and activates ERK1/2 phosphorylation in the absence of exogenously added glutamate (EC₅₀=163.3 nM) .

HY-14909

Bardoxolone 15+ Cited Publications CDDO; RTA 401	Keap1-Nrf2 Necroptosis	Metabolic Disease Cancer
Bardoxolone (RTA 401; CDDO) is a novel nuclear regulatory factor (NRf-2) activator. Bardoxolone is a potent necroptosis inhibitor that inhibits Z-VAD-FMK-induced necroptosis. Bardoxolone methyl enhances the antioxidant system, modulates inflammatory cytokines and inhibits apoptosis in rat kidney, demonstrating inhibition on APAP-induced acute kidney injury (AKI) and analgesic effect. Additionally, Bardoxolone methyl decreases Paclitaxel (PAC) (HY-B0015)-induced mitochondrial damage in neuronal cells. Bardoxolone methyl is promising for the research of chemotherapy-induced neuropathic pain and chronic kidney disease .

HY-15416

NS309	Potassium Channel	Cardiovascular Disease Neurological Disease
NS309 is a potent and selective activator of the Ca ²⁺-activated SK/IK potassium channels, but displays no activity at BK channels .

HY-W017540

Cyclocreatine 1 Publications Verification	ATP Synthase	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .

HY-B1065

Aceglutamide α-N-Acetyl-L-glutamine; N2-Acetylglutamine	Keap1-Nrf2 Akt ASK1 Apoptosis	Neurological Disease
Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) is a neuroprotectant that can penetrate the blood-brain barrier. Aceglutamide can enhance the antioxidant systems of glutathione (GSH), thioredoxin (Trx) and Nrf2. Aceglutamide also inhibits ASK1 and TRAF1, activates the Akt/Bcl-2 anti-apoptotic pathway, enhances the activity of antioxidant enzymes and reduces oxidative damage. Aceglutamide can improve neurological deficits after cerebral ischemia, reduce infarct volume, and inhibit neuronal apoptosis, especially substantia nigra dopaminergic neurons. Aceglutamide can reduce cerebral ischemia/reperfusion injury, improve motor dysfunction, and is used in ischemic stroke-related research .

HY-100355

C18-Ceramide	Endogenous Metabolite	Neurological Disease Cancer
C18-Ceramide is a bioactive molecule with multiple functions in cells, can cross the blood-brain barrier, not a traditional agonist or inhibitor targeting a single site. It can act on multiple cellular targets, such as proteins related to endoplasmic reticulum stress (e.g., ATF-4, XBP-1, CHOP), proteins in the PI3K/AKT signaling pathway, and SNARE complex proteins. It exerts activities like inducing cell death, promoting autophagy, and regulating exocytosis through mechanisms such as activating endoplasmic reticulum stress, inhibiting the PI3K/AKT signaling pathway, and affecting lipid raft - related functions. It can be used in research on the mechanism of neuronal injury in the field of neuroscience and in the treatment research of cancers such as glioma in the field of oncology .

HY-B1065R

Aceglutamide (Standard) α-N-Acetyl-L-glutamine (Standard); N2-Acetylglutamine (Standard)	Keap1-Nrf2 Akt ASK1 Apoptosis	Neurological Disease
Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) (Standard) is the analytical standard of Aceglutamide (HY-B1065). This product is intended for research and analytical applications. Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) is a neuroprotectant that can penetrate the blood-brain barrier. Aceglutamide can enhance the antioxidant systems of glutathione (GSH), thioredoxin (Trx) and Nrf2. Aceglutamide also inhibits ASK1 and TRAF1, activates the Akt/Bcl-2 anti-apoptotic pathway, enhances the activity of antioxidant enzymes and reduces oxidative damage. Aceglutamide can improve neurological deficits after cerebral ischemia, reduce infarct volume, and inhibit neuronal apoptosis, especially substantia nigra dopaminergic neurons. Aceglutamide can reduce cerebral ischemia/reperfusion injury, improve motor dysfunction, and is used in ischemic stroke-related research .

HY-P5117

TAT-CIRP	Toll-like Receptor (TLR)	Neurological Disease
TAT-CIRP is a a small peptide, refers to Trans-trans-activating (Tat)-cold-inducible RNA binding protein. TAT-CIRP is an inhibitor of myeloid differentiation protein 2 (MD2). TAT-CIRP exhibits robust neuroprotection against ischemic and hemorrhagic stroke in mice .

Cat. No.	Product Name	Target	Research Area

HY-P3400

LP17 1 Publications Verification LQVTDSGLYRCVIYHPP	Peptides	Neurological Disease
LP17 (LQVTDSGLYRCVIYHPP) is a BBB-penetrable triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LP17 substantially alleviates ischemia-induced infarction and neuronal injury. LP17 can get access into brain and block TREM-1 .

HY-P3400A

LP17 TFA 1 Publications Verification LQVTDSGLYRCVIYHPP TFA	Peptides	Neurological Disease
LP17 (LQVTDSGLYRCVIYHPP) TFA is a BBB-penetrable triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LP17 TFA substantially alleviates ischemia-induced infarction and neuronal injury. LP17 TFA can get access into brain and block TREM-1 .